325 related articles for article (PubMed ID: 33912187)
1. Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes.
Abbas HA; Reville PK; Jiang X; Yang H; Reuben A; Im JS; Little L; Sinson JC; Chen K; Futreal A; Garcia-Manero G
Front Immunol; 2021; 12():659625. PubMed ID: 33912187
[TBL] [Abstract][Full Text] [Related]
2. High-throughput sequencing of CD4
Wang L; Zhang P; Li J; Lu H; Peng L; Ling J; Zhang X; Zeng X; Zhao Y; Zhang W
Arthritis Res Ther; 2019 Dec; 21(1):295. PubMed ID: 31856905
[TBL] [Abstract][Full Text] [Related]
3. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression.
Kochenderfer JN; Kobayashi S; Wieder ED; Su C; Molldrem JJ
Blood; 2002 Nov; 100(10):3639-45. PubMed ID: 12393644
[TBL] [Abstract][Full Text] [Related]
4. Application of the molecular analysis of the T-cell receptor repertoire in the study of immune-mediated hematologic diseases.
Plasilova M; Risitano A; Maciejewski JP
Hematology; 2003 Jun; 8(3):173-81. PubMed ID: 12745651
[TBL] [Abstract][Full Text] [Related]
5. Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
Bewersdorf JP; Zeidan AM
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101245. PubMed ID: 33762100
[TBL] [Abstract][Full Text] [Related]
6. Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome.
Campregher PV; Srivastava SK; Deeg HJ; Robins HS; Warren EH
Exp Hematol; 2010 Mar; 38(3):202-12. PubMed ID: 20035823
[TBL] [Abstract][Full Text] [Related]
7. Azacitidine improves the T-cell repertoire in patients with myelodysplastic syndromes and acute myeloid leukemia with multilineage dysplasia.
Fozza C; Corda G; Barraqueddu F; Virdis P; Contini S; Galleu A; Isoni A; Dore F; Angelucci E; Longinotti M
Leuk Res; 2015 Sep; 39(9):957-63. PubMed ID: 26209197
[TBL] [Abstract][Full Text] [Related]
8. Molecular strategies for detection and quantitation of clonal cytotoxic T-cell responses in aplastic anemia and myelodysplastic syndrome.
Wlodarski MW; Gondek LP; Nearman ZP; Plasilova M; Kalaycio M; Hsi ED; Maciejewski JP
Blood; 2006 Oct; 108(8):2632-41. PubMed ID: 16614248
[TBL] [Abstract][Full Text] [Related]
9. Paired TCRαβ analysis of virus-specific CD8(+) T cells exposes diversity in a previously defined 'narrow' repertoire.
Cukalac T; Kan WT; Dash P; Guan J; Quinn KM; Gras S; Thomas PG; La Gruta NL
Immunol Cell Biol; 2015 Oct; 93(9):804-14. PubMed ID: 25804828
[TBL] [Abstract][Full Text] [Related]
10. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones.
Maciejewski JP; O'Keefe C; Gondek L; Tiu R
Folia Histochem Cytobiol; 2007; 45(1):5-14. PubMed ID: 17378239
[TBL] [Abstract][Full Text] [Related]
11. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
[TBL] [Abstract][Full Text] [Related]
12. Analysis of TCR Repertoire by High-Throughput Sequencing Indicates the Feature of T Cell Immune Response after SARS-CoV-2 Infection.
Wang Y; Duan F; Zhu Z; Yu M; Jia X; Dai H; Wang P; Qiu X; Lu Y; Huang J
Cells; 2021 Dec; 11(1):. PubMed ID: 35011632
[TBL] [Abstract][Full Text] [Related]
13. Evidence for Selective Benefit of Sequential Treatment With Hypomethylating Agents in Patients With Myelodysplastic Syndrome.
Apuri S; Al Ali N; Padron E; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Apr; 17(4):211-214. PubMed ID: 28185797
[TBL] [Abstract][Full Text] [Related]
14. Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation.
Gkazi AS; Margetts BK; Attenborough T; Mhaldien L; Standing JF; Oakes T; Heather JM; Booth J; Pasquet M; Chiesa R; Veys P; Klein N; Chain B; Callard R; Adams SP
Front Immunol; 2018; 9():2547. PubMed ID: 30455696
[TBL] [Abstract][Full Text] [Related]
15. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset.
Fozza C; Contini S; Galleu A; Simula MP; Virdis P; Bonfigli S; Longinotti M
Exp Hematol; 2009 Aug; 37(8):947-55. PubMed ID: 19409953
[TBL] [Abstract][Full Text] [Related]
16. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing.
Risitano AM; Maciejewski JP; Green S; Plasilova M; Zeng W; Young NS
Lancet; 2004 Jul 24-30; 364(9431):355-64. PubMed ID: 15276395
[TBL] [Abstract][Full Text] [Related]
17. [T cell repertoires correlate with pathogenesis of chronic idiopathic thrombocytopenic purpura].
Zhu X; Zhu P; Guo XL
Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3316-22. PubMed ID: 16409835
[TBL] [Abstract][Full Text] [Related]
18. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine.
Borthakur G; Ahdab SE; Ravandi F; Faderl S; Ferrajoli A; Newman B; Issa JP; Kantarjian H
Leuk Lymphoma; 2008 Apr; 49(4):690-5. PubMed ID: 18398735
[TBL] [Abstract][Full Text] [Related]
19. Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.
Peng J; Hasserjian RP; Tang G; Patel KP; Goswami M; Jabbour EJ; Garcia-Manero G; Medeiros LJ; Wang SA
Leuk Lymphoma; 2016; 57(4):812-9. PubMed ID: 26293512
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating agent based combinations in higher risk myelodysplastic syndrome.
Chandhok NS; Lewis R; Prebet T
Leuk Lymphoma; 2020 May; 61(5):1012-1027. PubMed ID: 31814484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
